NASDAQ:PSTV Plus Therapeutics Q1 2025 Earnings Report $0.82 -0.07 (-7.69%) Closing price 04:00 PM EasternExtended Trading$0.82 +0.00 (+0.35%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Plus Therapeutics EPS ResultsActual EPS-$0.56Consensus EPS -$0.17Beat/MissMissed by -$0.39One Year Ago EPSN/APlus Therapeutics Revenue ResultsActual Revenue$1.06 millionExpected Revenue$1.11 millionBeat/MissMissed by -$53.00 thousandYoY Revenue GrowthN/APlus Therapeutics Announcement DetailsQuarterQ1 2025Date5/30/2025TimeBefore Market OpensConference Call DateFriday, May 30, 2025Conference Call Time4:00PM ETUpcoming EarningsPlus Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Plus Therapeutics Earnings HeadlinesAscendiant Capital Maintains Plus Therapeutics (PSTV) Buy RecommendationOctober 6 at 3:14 PM | msn.comPlus Therapeutics (NASDAQ:PSTV) Earns Buy Rating from D. Boral CapitalSeptember 27, 2025 | americanbankingnews.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.October 7 at 2:00 AM | Brownstone Research (Ad)Plus Therapeutics (PSTV) Soars 40% as Firm Seals Partnership with United HealthcareSeptember 26, 2025 | insidermonkey.comD. Boral Capital Maintains Plus Therapeutics (PSTV) Buy RecommendationSeptember 25, 2025 | msn.comThese 3 Penny Stocks are Soaring Today: PLUS, EVAX, DVLTSeptember 25, 2025 | 247wallst.comSee More Plus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Plus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your email. Email Address About Plus TherapeuticsPlus Therapeutics (NASDAQ:PSTV) is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases. The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors. Plus Therapeutics has secured orphan drug and rare pediatric disease designations for select compounds, reflecting its focus on addressing unmet needs in both adult and pediatric oncology. Clinical studies are conducted in collaboration with academic medical centers and contract research organizations across North America. Headquartered in Austin, Texas, Plus Therapeutics is led by an executive team with extensive experience in radiopharmaceuticals and oncology drug development. The company maintains research, manufacturing and administrative operations in the United States and continues to expand strategic partnerships to advance its targeted radiotherapeutic portfolio.View Plus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings PepsiCo (10/9/2025)Fastenal (10/13/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
